Protocol Ledger

NCT06680596 · Phase II · RECRUITING

Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy

Interventional Phase II clinical trial protocol NCT06680596 sponsored by UNICANCER in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-07-30 Enrollment: 80 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06680596
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)80 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06680596
Protocol FieldVerified Registry Value
NCT IdentifierNCT06680596
Consolidated Lead SponsorUNICANCER
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment80 participants (ESTIMATED)
Registered Start Date2025-07-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06680596
Hospital Research SiteLocationSite Profile
Centre Jean PerrinClermont-Ferrand, FranceOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI